EURneffy Nasal Spray Shows Strong PK/PD in Allergic Rhinitis, With Anne Ellis, MD

Last month at the European Academy of Allergy & Clinical Immunology Congress meeting in Glasgow, United Kingdom (June 13 – 16, 2025), new data was presented on EURneffy (2 mg), an adrenaline nasal spray, for allergic rhinitis, showing comparable pharmacokinetic (PK)/pharmacodynamic (PD) responses to intramuscular adrenaline 0.3 mg administered manually,

In August 2024, the European Commission approved EURneffy 2mg, a compact nasal spray designed to provide rapid absorption of adrenaline (epinephrine), for idiopathic or exercise-induced anaphylaxis in adults and children weighing ≥ 30 kg. EURneffy offers an alternative option to injectables, and it is simple to use, non-invasive, more convenient to carry and use, has a longer shelf life of 30 months, and exhibits better temperature stability than existing adrenaline auto-injectors. While adrenaline nasal spray is already approved and available to use in the US as neffy, European countries are still securing market access for EURneffy; ALK expects to start launching the product in Q3 2025.

As a part of our meeting coverage, HCPLive spoke with lead investigator Anne Ellis, professor and chair of the division of allergy and immunology at the department of medicine at Queen’s University in Canada, on promising findings of a randomized, crossover, PK/PD study.

“The study was looking at whether or not having allergic rhinitis or allergy symptoms, nasal allergies, would interfere with how well the epinephrine from the nasal adrenaline spray would work,” Ellis said. “Fortunately, what was found is that we still achieved appropriate levels of epinephrine in the blood. In fact, if anything, slightly higher levels were achieved when people had induced symptoms of allergic rhinitis. So, there's no concern that if you're stuffed up with your allergies, that nasal epinephrine wouldn't work if you were needing to treat you treat an allergic reaction with it.”

The PK/PD study examined EURneffy 2 mg in > 700 participants, demonstrating no serious adverse events. After comparing the pharmacodynamics and pharmacokinetics across a range of dosing conditions—single and repeat dosing, self-administration, dosing in pediatrics, and among patients with multiple nasal conditions that may cause congestion and rhinorrhea—the clinical pharmacological data of 2 doses of EURneffy 2 mg was comparable to 2 doses of a 0.3 mg intramuscular adrenaline injection.

“What we saw was the pharmacokinetic properties were slightly enhanced in the setting of allergic rhinitis, which is a good thing, so you don't have to worry about not getting the epinephrine administered just because you're stuffy,” Ellis said. “The pharmacodynamics were identical, if not slightly better, with neffy compared to the intramuscular injection of epinephrine, which is a traditional route. So very reassuring and exciting findings that, even in the throes of that allergy season, neffy will still work for your acute allergic reactions.”

Ellis has no reported disclosures.